Table 2 |
||
|
Body composition and bone mineral density at the 3-month visit (time for randomisation) |
||
|
Treatment A (n = 22) |
Treatment B (n = 18) |
|
|
|
||
|
Body mass index (kg/m2) |
27.7 (6.4) |
24.7 (3.7) |
|
Fat mass (kg) |
30.5 (12.9) |
24.4 (7.5) |
|
Fat mass index (kg/m2) |
10.9 (4.8) |
8.7 (2.9) |
|
Fat (%) |
38.8 (8.3) |
35.7 (7.9) |
|
Trunk:peripheral fat ratio |
1.3 (0.3) |
1.2 (0.4) |
|
Trunk fat (kg) |
16.4 (7.2) |
13.9 (6.6) |
|
Lean body mass (kg) |
45.8 (8.8) |
43.4 (9.0) |
|
Appendicular lean mass (kg) |
19.9 (4.4) |
18.7 (4.4) |
|
Fat-free mass (kg) |
48.3 (9.1) |
45.9 (9.4) |
|
Fat-free mass index (kg/m2) |
17.0 (2.5) |
16.1 (2.1) |
|
L2 to L4 |
||
|
Bone mineral density (g/cm2) |
1.18 (0.19) |
1.06 (0.14) |
|
Z score |
0.68 (1.40) |
-0.66 (0.89) |
|
T score |
-0.31 (1.55) |
-1.26 (1.18) |
|
Femoral neck |
||
|
Bone mineral density (g/cm2) |
0.98 (0.16) |
0.92 (0.11) |
|
Z score |
0.50 (1.04) |
-0.16 (0.79) |
|
T score |
-0.32 (1.25) |
-0.82 (0.95) |
|
|
||
|
Data presented as mean (standard deviation). Treatment A, methotrexate + sulphasalazine + hydroxychloroquine; treatment B, methotrexate +infliximab. |
||
|
Engvall et al. Arthritis Research & Therapy 2010 12:R197 doi:10.1186/ar3169 |
||
